31-Dec-2025
TipRanks (Mon, 29-Dec 8:20 AM ET)
EWTX Reports Strong Safety Profile for EDG-7500 in HCM as Phase 2 Study Achieves Key Milestones
Market Chameleon (Wed, 24-Dec 5:31 AM ET)
Market Chameleon (Wed, 24-Dec 4:16 AM ET)
PRNewswire (Wed, 24-Dec 8:00 AM ET)
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
PRNewswire (Tue, 2-Dec 8:01 AM ET)
PRNewswire (Thu, 20-Nov 8:00 AM ET)
Market Chameleon (Mon, 10-Nov 3:44 AM ET)
PRNewswire (Mon, 10-Nov 8:00 AM ET)
Edgewise Therapeutics to Participate in Upcoming Investor Conferences
PRNewswire (Fri, 7-Nov 8:00 AM ET)
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
Edgewise Therapeutics trades on the NASDAQ stock market under the symbol EWTX.
As of December 31, 2025, EWTX stock price climbed to $24.82 with 1,020,306 million shares trading.
EWTX has a beta of 2.82, meaning it tends to be more sensitive to market movements. EWTX has a correlation of 0.27 to the broad based SPY ETF.
EWTX has a market cap of $2.63 billion. This is considered a Mid Cap stock.
In the last 3 years, EWTX traded as high as $38.12 and as low as $5.12.
The top ETF exchange traded funds that EWTX belongs to (by Net Assets): VTI, IWM, VXF, IWO, IBB.
EWTX has underperformed the market in the last year with a return of -8.3%, while SPY returned +17.2%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in EWTX shares. However, EWTX has outperformed the market in the last 3 month and 2 week periods, returning +53.0% and +9.0%, while SPY returned +2.7% and +0.7%, respectively. This indicates EWTX has been having a stronger performance recently.
EWTX support price is $23.07 and resistance is $26.01 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that EWTX shares will trade within this expected range on the day.